| 1 |
王 蓉，时国朝，张云辉. 慢性阻塞性肺疾病与气道微生物群关系的研究现状[J]. 国际呼吸杂志，2022, 42(2): 144-150.
|
| 2 |
陈华萍，甘志新，刘 刚，等. 慢性阻塞性肺疾病的合并症/并发症的发病率和病死率分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 417-421.
|
| 3 |
Lareau SC, Fahy B, Meek P, et al. Chronic obstructive pulmonary disease (COPD)[J]. Am J Respir Crit Care Med, 2019, 199(1): 1-2.
|
| 4 |
O′Donnell DE, Milne KM, James MD, et al. Dyspnea in COPD: New mechanistic insights and management implications[J]. Adv Ther, 2020, 37(1): 41-60.
|
| 5 |
Shyam Prasad Shetty B, Chaya SK, Kumar VS, et al. Inflammatory biomarkers interleukin 1 Beta (IL-1β) and tumour necrosis factor alpha (TNF-α) are differentially elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD[J]. Toxics, 2021, 9(4): 72-75.
|
| 6 |
Dogra M, Jaggi S, Aggarwal D, et al. Role of interleukin-6 and insulin resistance as screening markers for metabolic syndrome in patients of chronic obstructive pulmonary disease. A hospital-based cross-sectional study[J]. Monaldi Arch Chest Dis, 2021, 92(3): 10.
|
| 7 |
张曙晴，张骆军，周小林，等. 慢性阻塞性肺疾病患者血清IL-33、sST2、CRP水平与病情严重程度的相关性研究[J]. 中国实验诊断学，2021, 25(11): 1610-1613.
|
| 8 |
乔丽旻，张泽明，王 静，等. FEV1%pred与SGRQ、mMRC、CAT评分在COPD患者中的相关性研究[J]. 国际呼吸杂志，2021, 41(19): 1493-1499.
|
| 9 |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南[J]. 中华结核和呼吸杂志，2002, 25(8): 453-460.
|
| 10 |
Osei ET, Brandsma CA, Timens W, et al. Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD[J]. Eur Respir J, 2020, 55(2): 190-195.
|
| 11 |
Kubysheva N, Boldina M, Eliseeva T, et al. Relationship of serum levels of IL-17, IL-18, TNF-α，and lung function parameters in patients with COPD, asthma-COPD overlap, and bronchial asthma[J]. Mediators Inflamm, 2020, 20(12): 465-489.
|
| 12 |
Singh R, Narang M, Dawson L, et al. Could disease severity and inflammatory markers (IL-6, Hs-CRP, TNF-α) be related to frailty in COPD? A prospective study[J]. J Assoc Physicians India, 2022, 70(4): 11-12.
|
| 13 |
Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis[J]. Thorax, 2019, 74(5): 439-446.
|
| 14 |
Paplinska-Goryca M, Misiukiewicz-Stepien P, Proboszcz M, et al. The expressions of TSLP, IL-33, and IL-17A in monocyte derived dendritic cells from asthma and COPD patients are related to epithelial-macrophage interactions[J]. Cells, 2020, 9(9): 1944-1951.
|
| 15 |
Venkatachalam P, Dwivedi DP, Govindraj V. FEV1/FEV6 is effective as a surrogate for FEV1/FVC in the diagnosis of chronic obstructive pulmonary disease[J]. Indian J Tuberc, 2021, 68(2): 230-235.
|
| 16 |
Huang H, Huang X, Zeng K, et al. Interleukin-6 is a strong predictor of the frequency of COPD exacerbation within 1 year[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16(10): 2945-2951.
|
| 17 |
Kim RY, Oliver BG, Wark PAB, et al. COPD exacerbations: targeting IL-33 as a new therapy[J]. Lancet Respir Med, 2021, 9(11): 1213-1214.
|
| 18 |
Dai YC, Wang WD, Zhang JA, et al. MTB driven B cells producing IL-35 and secreting high level of IL-10 in the patients with active pulmonary tuberculosis[J]. Mol Immunol, 2019, 112(10): 175-181.
|
| 19 |
曹丽娇，袁开芬. COPD急性加重期患者血清白细胞介素6、降钙素原、超敏C反应蛋白水平与甲状腺功能的相关性研究[J]. 国际呼吸杂志，2021, 41(19): 1468-1475.
|
| 20 |
Joo H, Park SJ, Min KH, et al. Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease published correction appears in BMC Pulm Med[J]. BMC Pulm Med, 2021, 21(1): 86-86.
|
| 21 |
赖育庭，黄 慧. 白介素6、降钙素原、D二聚体、肿瘤坏死因子-α、干扰素γ与慢阻肺急性加重期患者病情及预后的相关性研究[J]. 齐齐哈尔医学院学报，2023, 44(7): 601-606.
|
| 22 |
王婧雯，孙 辉，路 尧. 血清IL-33表达水平对慢性阻塞性肺疾病患者发生急性加重的预测价值[J]. 齐齐哈尔医学院学报，2022, 43(18): 1732-1735.
|
| 23 |
Li J, Rong L, Cui R, et al. Dynamic changes in serum IL-6, IL-8, and IL-10 predict the outcome of ICU patients with severe COVID-19[J]. Ann Palliat Med, 2021, 10(4): 3706-3714.
|
| 24 |
Zhao N, Dong C. Correlation of Serum IL-18, BDNF, and IL-1β with depression and prognosis after acute exacerbation of chronic obstructive pulmonary disease[J]. Comput Math Methods Med, 2022, 30(10): 355-359.
|
| 25 |
Rong B, Liu Y, Li M, et al. Correlation of serum levels of HIF-1α and IL-19 with the disease progression of COPD: a retrospective study[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13(21): 3791-3803.
|
| 26 |
Xu YR, Wang AL, Li Ya Q. Hypoxia-inducible factor 1-alpha is a driving mechanism linking chronic obstructive pulmonary disease to lung cancer[J]. Front Oncol, 2022, 12: 984525.
|
| 27 |
Shi L, Zhu BJ, Xu ML, et al. Selection of AECOPD-specific immunomodulatory biomarkers by integrating genomics and proteomics with clinical informatics[J]. Cell Biol Toxicol, 2018, 34(2): 109-123.
|
| 28 |
Zou SC, Pang LL, Mao QS, et al. IL-9 exacerbates the development of chronic obstructive pulmonary disease through oxidative stress[J]. Eur Rev Med Pharmacol Sci, 2018, 22(24): 8877-8884.
|
| 29 |
Zhang HX, Yang JJ, Zhang SA, et al. HIF-1α promotes inflammatory response of chronic obstructive pulmonary disease by activating EGFR/PI3K/AKT pathway[J]. Eur Rev Med Pharmacol Sci, 2018, 22(18): 6077-6084.
|
| 30 |
Chen H, Song ZJ, Qia MJ, et al. Selection of disease-specific biomarkers by integrating inflammatory mediators with clinical informatics in AECOPD patients: a preliminary study[J]. J Cell Mol Med, 2012，16(6): 1286-1297.
|